Is Axsome Therapeutics a good buy?
Out of 6 analysts, 3 (50%) are recommending AXSM as a Strong Buy, 2 (33.33%) are recommending AXSM as a Buy, 1 (16.67%) are recommending AXSM as a Hold, 0 (0%) are recommending AXSM as a Sell, and 0 (0%) are recommending AXSM as a Strong Sell. What is AXSM’s earnings growth forecast for 2022-2024?
What does Axsome therapeutics do?
Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for central nervous system (CNS) conditions that have limited treatment options. Through development of therapeutic options with novel mechanisms of action, we are transforming the approach to treating CNS conditions.
Where is Axsome located?
New York, NY
Company Description: Axsome Therapeutics, Inc. is located in New York, NY, United States and is part of the Scientific Research and Development Services Industry.
When will AXS-05 be available?
The company said in January the deficiencies stem from the “analytical methods in the chemistry, manufacturing and controls section” of the new drug application. Mizuho said even amid the delay, it still expects AXS-05 to be approved as early as late 2022.
Will Axsome Therapeutics stock go up?
The 14 analysts offering 12-month price forecasts for Axsome Therapeutics Inc have a median target of 60.00, with a high estimate of 180.00 and a low estimate of 27.00. The median estimate represents a +149.48% increase from the last price of 24.05.
Will AXS 05 get FDA approval?
Recent History of AXS-05 On 4/26/21, Axsome announced that AXS-05’s NDA application for MDD, which holds a Breakthrough Therapy Designation (BTD; awarded in March 2019), had been accepted by the FDA and granted Priority Review status.
Is AXS-05 approved?
a new approach to treating AXS-05 consists of a proprietary formulation and dose of dextromethorphan (DM) and bupropion. The safety and effectiveness of AXS-05 in Alzheimer’s disease agitation and smoking cessation have not been established and it is not approved by the FDA for these indications.
What is AXS 07?
AXS-07 is a novel, oral, rapidly absorbed, multi-mechanistic investigational medicine for the acute treatment of migraine, consisting of MoSEIC™ meloxicam and rizatriptan.
What is AXS 05?
AXS-05 (dextromethorphan-bupropion) is an oral NMDA receptor antagonist and sigma-1 receptor agonist, which utilizes inhibition of CYP2D6 to increase its bioavailability. This phase 2 trial assessed the efficacy and safety of dextromethorphan-bupropion in the treatment of major depressive disorder.
Will AXS-05 get approved?
Why is Axsome stock dropping?
Shares of Axsome Therapeutics (AXSM 6.28%) have sunk 19.8% as of 10:36 a.m. ET on Monday. The decline comes after the company revealed that it expects to receive a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for AXS-07 in treating migraine.
Is AXSM a Buy now?
Axsome Therapeutics Inc (NASDAQ:AXSM) The 15 analysts offering 12-month price forecasts for Axsome Therapeutics Inc have a median target of 62.00, with a high estimate of 180.00 and a low estimate of 27.00. The median estimate represents a +148.20% increase from the last price of 24.98.
What are the new antidepressants on the market?
The Food and Drug Administration (FDA) recently approved two new antidepressant medications that represent new approaches to treating depression: brexanolone and esketamine. Both of these medications carry a black box warning, which is the most serious warning from the FDA.
Where can I buy Axsm stock?
Shares of AXSM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Should you buy AXSM stock Stockinvest?
Our recommended stop-loss: We hold a negative evaluation for this stock.